Verastem (VSTM) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Verastem NASDAQ: VSTM is preparing a broad development program for its experimental cancer drug VS-7375, with incoming CEO Michael Bailey saying the company is considering both partnerships and a potential independent la…

Verastem NASDAQ: VSTM plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile executives said was com…

Verastem NASDAQ: VSTM is advancing its experimental KRAS G12D inhibitor VS-7375 toward potential accelerated approval in pancreatic cancer, with plans to expand studies in colorectal and lung cancers, company executives …

Verastem NASDAQ: VSTM reported $24 million in third-quarter 2026 net product revenue as refills of its ovarian cancer treatment offset a moderation in new patient starts. The company also outlined plans to begin a late-s…

Verastem, Inc. ( VSTM ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Julissa Viana - Senior Vice President of Corporate Communications, Investor Relations & Patient Advocacy Daniel Paterson - P…

Verastem (VSTM) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $1.35 per share a year ago.…

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the thir…

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is s…

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a …

Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript…

Verastem NASDAQ: VSTM presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma, colorectal cancer a…

Verastem Oncology (NASDAQ:VSTM) reported encouraging early clinical results for its experimental KRAS G12D inhibitor VS-7375, with the drug demonstrating antitumor activity across pancreatic, colorectal, and lung cancers…

Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.…

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-…

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has be…

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers.…

The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean …

Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor, VS-7375, in multiple cancers. Q2 '26 net product revenues reached $25.1M in just the fourth quar…

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restrict…

Verastem (NASDAQ: VSTM - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at BTIG Research in a research note issued to investors on Monday, Benzinga reports. They currently have a $18.00 target…

Verastem (NASDAQ: VSTM - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report released on Monday, MarketBeat Ratings reports. They presently have a $18.00 target price on …

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC.…

Verastem (NASDAQ: VSTM - Get Free Report) and Sangamo Therapeutics (NASDAQ: SGMO - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on …

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.…

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026.…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 18. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.
Quiet tape today.

